Skip to content

Intra-Cellular Therapies, Inc.: 10-K filed 2022-03-01

What Intra-Cellular Therapies, Inc. reported in its annual report filed 2022-03-01 (fiscal FY 2021): 43 published measures, 137 facts as tagged in accession 0001193125-22-059849.

This filing

Form
10-K (annual report)
Filed
2022-03-01
Fiscal period
fiscal FY 2021
Accession
0001193125-22-059849 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Intra-Cellular Therapies, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-12-31489,922,096USD
At 2020-12-31717,313,674USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-12-3172,031,421USD
At 2020-12-3160,453,570USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-12-31417,890,675USD
At 2020-12-31656,860,104USD
At 2019-12-31195,007,271USD
At 2018-12-31317,714,881USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-12-3192,364,990USD
At 2020-12-3160,045,933USD
At 2019-12-31107,636,849USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-10-01 to 2021-12-31-85,733,937USD92
2021-01-01 to 2021-12-31-284,125,666USD365
2021-07-01 to 2021-09-30-76,908,004USD92
2021-04-01 to 2021-06-30-68,743,782USD91
2021-01-01 to 2021-03-31-52,739,943USD90
2020-10-01 to 2020-12-31-60,699,178USD92
2020-01-01 to 2020-12-31-227,005,663USD366
2020-07-01 to 2020-09-30-55,183,625USD92
2020-04-01 to 2020-06-30-63,712,258USD91
2020-01-01 to 2020-03-31-47,410,602USD91
2019-01-01 to 2019-12-31-147,722,178USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-259,543,485USD365
2020-01-01 to 2020-12-31-230,072,845USD366
2019-01-01 to 2019-12-31-127,983,241USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2021-01-01 to 2021-12-31325,738USD365
2020-01-01 to 2020-12-31266,724USD366
2019-01-01 to 2019-12-31700,395USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2021-10-01 to 2021-12-3125,670,926USD92
2021-07-01 to 2021-09-3022,207,201USD92
2021-04-01 to 2021-06-3020,046,561USD91
2021-01-01 to 2021-03-3115,878,329USD90
2020-10-01 to 2020-12-3112,454,270USD92
2020-07-01 to 2020-09-307,368,594USD92
2020-04-01 to 2020-06-301,906,636USD91
2020-01-01 to 2020-03-311,083,479USD91

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2021-01-01 to 2021-12-3183,803,017USD365
2020-01-01 to 2020-12-3122,812,979USD366
2019-01-01 to 2019-12-3160,613USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-01-01 to 2021-12-3111,518,911USD365
2020-01-01 to 2020-12-31664,176,929USD366
2019-01-01 to 2019-12-313,235,601USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-01-01 to 2021-12-31280,343,631USD365
2020-01-01 to 2020-12-31-480,295,000USD366
2019-01-01 to 2019-12-31177,436,987USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-12-31-1,221,229,698USD
At 2020-12-31-937,104,032USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2021-01-01 to 2021-12-315,631USD365
2021-07-01 to 2021-09-3023,125USD92
2021-04-01 to 2021-06-30-23,756USD91
2021-01-01 to 2021-03-31-5,000USD90
2020-10-01 to 2020-12-31-10,232USD92
2020-01-01 to 2020-12-3113,513USD366
2020-01-01 to 2020-03-31-3,281USD91
2019-01-01 to 2019-12-311,600USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-12-311,790,724USD
At 2020-12-311,998,346USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2021-01-01 to 2021-12-3134,303,029USD365
2020-01-01 to 2020-12-3124,115,197USD366
2019-01-01 to 2019-12-3120,788,688USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-285,688,125USD365
2020-01-01 to 2020-12-31-231,227,631USD366
2019-01-01 to 2019-12-31-154,011,850USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-12-31467,280,830USD
At 2020-12-31690,904,482USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-12-3153,356,478USD
At 2020-12-3136,853,223USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2021-12-318,691,220USD
At 2020-12-315,501,825USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2021-12-3120,155,994USD
At 2020-12-3110,764,583USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2021-10-01 to 2021-12-31111,675,480USD92
2021-01-01 to 2021-12-31369,491,142USD365
2021-07-01 to 2021-09-3099,531,025USD92
2021-04-01 to 2021-06-3089,187,615USD91
2021-01-01 to 2021-03-3169,097,022USD90
2020-10-01 to 2020-12-3173,787,606USD92
2020-01-01 to 2020-12-31254,040,610USD366
2020-07-01 to 2020-09-3063,305,048USD92
2020-04-01 to 2020-06-3066,778,953USD91
2020-01-01 to 2020-03-3150,169,003USD91
2019-01-01 to 2019-12-31154,072,463USD365

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2021-12-317,948,126USD
At 2020-12-317,056,385USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2021-01-01 to 2021-12-3188,845,513USD365
2020-01-01 to 2020-12-3165,782,137USD366
2019-01-01 to 2019-12-3189,124,838USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-12-3181,886,965shares
At 2020-12-3180,463,089shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2021-12-3193,764,990USD
At 2020-12-3161,445,933USD
At 2019-12-31107,636,849USD
At 2018-12-3154,947,502USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2021-12-31-363,653USD
At 2020-12-31480,584USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2021-12-3120,764,458USD
At 2020-12-3124,324,762USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2021-12-3125,400,000USD
At 2020-12-3129,100,000USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2021-12-316,359,391USD
At 2020-12-316,034,895USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2021-12-314,568,667USD
At 2020-12-314,036,549USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2021-12-3186,084USD
At 2020-12-3186,084USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2021-12-3125,443,372USD
At 2020-12-3114,235,455USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-284,120,035USD365
2020-01-01 to 2020-12-31-226,992,150USD366
2019-01-01 to 2019-12-31-147,720,578USD365

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-284,125,666USD365
2020-01-01 to 2020-12-31-227,005,663USD366
2019-01-01 to 2019-12-31-147,722,178USD365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-284,969,903USD365
2020-01-01 to 2020-12-31-226,653,396USD366
2019-01-01 to 2019-12-31-146,926,104USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2021-01-01 to 2021-12-31272,611,040USD365
2020-01-01 to 2020-12-31186,363,444USD366
2019-01-01 to 2019-12-3164,947,625USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2021-01-01 to 2021-12-31533,360USD365
2020-01-01 to 2020-12-31528,118USD366
2019-01-01 to 2019-12-31477,121USD365

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2021-01-01 to 2021-12-315,631USD365
2020-01-01 to 2020-12-3113,513USD366
2019-01-01 to 2019-12-311,600USD365

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-53,070,458USD365
2020-01-01 to 2020-12-31-40,049,094USD366
2019-01-01 to 2019-12-31-8,484,822USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2021-01-01 to 2021-12-310USD365
2020-01-01 to 2020-12-31652,712,011USD366

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-12-319,391,411USD365
2020-01-01 to 2020-12-3110,764,583USD366

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-12-31891,741USD365
2020-01-01 to 2020-12-317,056,385USD366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-12-313,189,395USD365
2020-01-01 to 2020-12-31-1,923,199USD366
2019-01-01 to 2019-12-31-6,536,036USD365

Inspect the source

Entity
Intra-Cellular Therapies, Inc. / CIK 0001567514
Captured
2026-09-21T17:20:04.465Z
SEC response SHA-256
d515a2828c30b442b80d2f88dbecd3b8d47803a78a686cc6f7c16f5ab9f2019e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001567514.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))